Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE), I-MAB (IMAB) and Cidara Therapeutics (CDTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Maze Therapeutics, Inc. (MAZE – Research Report), I-MAB (IMAB – Research Report) and Cidara Therapeutics (CDTX – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Maze Therapeutics, Inc. (MAZE)

In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Maze Therapeutics, Inc., with a price target of $50.00. The company’s shares closed last Thursday at $26.50.

According to TipRanks.com, Ghosh is a 4-star analyst with an average return of 21.6% and a 73.3% success rate. Ghosh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, ACADIA Pharmaceuticals, and Avidity Biosciences. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Maze Therapeutics, Inc. with a $34.83 average price target, implying a 33.9% upside from current levels. In a report issued on September 29, J.P. Morgan also maintained a Buy rating on the stock with a $37.00 price target.

See today’s best-performing stocks on TipRanks >>

I-MAB (IMAB)

In a report released today, Daina Graybosch from Leerink Partners initiated coverage with a Buy rating on I-MAB and a price target of $9.00. The company’s shares closed last Thursday at $4.13.

According to TipRanks.com, Graybosch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -13.4% and a 33.6% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Werewolf Therapeutics, Bolt Biotherapeutics, and Century Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for I-MAB with a $7.40 average price target, which is an 85.0% upside from current levels. In a report issued on October 1, BTIG also initiated coverage with a Buy rating on the stock with a $7.00 price target.

Cidara Therapeutics (CDTX)

In a report released today, Sara Nik from H.C. Wainwright reiterated a Buy rating on Cidara Therapeutics, with a price target of $110.00. The company’s shares closed last Thursday at $98.50.

According to TipRanks.com, Nik is a 3-star analyst with an average return of 9.4% and a 54.5% success rate. Nik covers the Healthcare sector, focusing on stocks such as Kairos Pharma, Ltd., Moleculin Biotech, and Curis. ;'>

Cidara Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $135.00, representing a 40.1% upside. In a report issued on September 24, WBB Securities also maintained a Buy rating on the stock with a $123.00 price target.

Read More on MAZE:

Disclaimer & DisclosureReport an Issue

• Two new option listings on September 17th
• Maze Therapeutics price target raised to $34 from $19 at Guggenheim
• Maze Therapeutics price target raised to $50 from $34 at H.C. Wainwright
• Maze Therapeutics Advances Clinical Programs Amid Financial Stability
• Maze Therapeutics price target raised to $37 from $30 at BTIG